Hodgkin Lymphoma is not a disease that finds no treatment these days. You can easily cure it by the best possible treatments.Only 20% of patients see the relapse of the condition. However there are patients who don’t respond well to the chemotherapy. Such patients can have limited scope of treatment. Here we have reviewed immune checkpoint inhibitor therapy in patients with relapsed or refractory Hodgkin lymphoma. Immune checkpoints have been shown to play a critical role in cancer immune evasion and the host antitumor response. This gives a good way to exploit the science here.
Alterations in chromosome 9p24.1 are commonly found in Hodgkin lymphoma and lead to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. The anti-PD-1 monoclonal antibodies pembrolizumab and nivolumab are the two most commonly used immune checkpoint inhibitors in the setting of relapsed or refractory Hodgkin lymphoma. A median progression-free survival of approximately 17 months in heavily pretreated patients with relapsed or refractory Hodgkin lymphoma was observed.Time to response with an immune checkpoint inhibitor usually occurs within the first few cycles, with between 9% and 22% of patients achieving a CR.
It is likely that evidently, immune checkpoint inhibitors have great potential and way out to be incorporated into frontline therapies, as in recently reported studies in which they are used in combination with adriamycin, vinblastine, dacarbazine chemotherapy, with the aim of improving response rates and durable responses for newly diagnosed patients with Hodgkin lymphoma
https://ascopubs.org/doi/full/10.1200/OP.20.01029
